Stay updated on ABP 980 vs Trastuzumab in HER2+ Early Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the ABP 980 vs Trastuzumab in HER2+ Early Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABP 980 vs Trastuzumab in HER2+ Early Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision indicator updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T02:43:39.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed on the page. The previously displayed lapse-in-funding notice and the Revision: v3.4.1 entry have been removed.
    Difference
    0.2%
    Check dated 2026-02-11T14:29:31.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide funding notice banner was added, informing users about a lapse in government funding and directing them to cc.nih.gov and opm.gov for status. The page revision now shows v3.4.1, replacing v3.4.0.
    Difference
    0.2%
    Check dated 2026-02-04T10:44:44.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a glossary toggle, updated QC metadata (Last Update Submitted that Met QC Criteria), and a site revision notice (Revision: v3.4.0). Removed the older QC label (Last Update Submitted that met QC Criteria), No FEAR Act data, and the previous Revision: v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-28T06:26:34.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4.
    Difference
    0.0%
    Check dated 2026-01-14T03:29:05.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Updated the study locations: new sites across multiple countries have been added and several existing locations removed. This changes where participants can enroll and where the study is conducted.
    Difference
    3%
    Check dated 2025-12-23T22:56:28.000Z thumbnail image

Stay in the know with updates to ABP 980 vs Trastuzumab in HER2+ Early Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABP 980 vs Trastuzumab in HER2+ Early Breast Cancer Clinical Trial page.